BioLineRX
BLRX
28 hedge funds and large institutions have $10.3M invested in BioLineRX in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.
661% more capital invested
Capital invested by funds: $1.36M → $10.3M (+$8.97M)
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
0% more funds holding
Funds holding: 28 → 28 (0)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$5.92M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.33M |
| 3 |
AC
Armistice Capital
New York
|
+$3.99M |
| 4 |
AWM
Apollon Wealth Management
Mount Pleasant,
South Carolina
|
+$69.6K |
| 5 |
VF
Virtu Financial
New York
|
+$43.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$30.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$29K |
| 3 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$25.6K |
| 4 |
TNB
Thomasville National Bank
Thomasville,
Georgia
|
-$13K |
| 5 |
LPL Financial
San Diego,
California
|
-$5.71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$29K | -569 | Closed |
|
|
TNB
28
Thomasville National Bank
Thomasville,
Georgia
| – | -$13K | -250 | Closed |
|
29
Citigroup
New York
| – | -$4K | -85 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | -$2.17K | -38 | -88% |
|
|
VVP
31
Venture Visionary Partners
Sylvania,
Ohio
| – | -$1.71K | -33 | Closed |
|
32
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -29 | Closed |
|
|
SPIA
33
Steward Partners Investment Advisory
New York
| – | -$1K | -25 | Closed |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| – | -$1K | -18 | Closed |
|
BLRX Hedge Fund Activity: Q3 2022 in Review
28 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2022, worth a combined $10.3M — up 661% from $1.36M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BLRX positions and 7 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $5.92M. The largest seller was Envestnet Asset Management, cutting an estimated $30.7K.
- 28 institutional investors held BioLineRX (BLRX) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $10.3M of BioLineRX stock for Q3 2022, up 661% quarter-over-quarter.
- 8 funds opened new BioLineRX positions in Q3 2022 and 7 closed out, a net change of +1 holder.
- The largest BioLineRX buyer in Q3 2022 was Altium Capital Management, an estimated $5.92M added.
- The largest BioLineRX seller in Q3 2022 was Envestnet Asset Management, an estimated $30.7K sold.
Based on aggregated 13F filings for Q3 2022.